|Bid||4.0800 x 3100|
|Ask||5.6700 x 800|
|Day's Range||4.9100 - 5.0600|
|52 Week Range||2.3900 - 6.0400|
|Beta (3Y Monthly)||0.86|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The big shareholder groups in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) have power over the company. Institutions...
We at Insider Monkey have gone over 738 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st. In this article, we look at what those funds think of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) based on that […]
Here are four stocks that appear to be at or near a breakout point: Enphase Energy, Inc . (NASDAQ: ENPH ) jumped 88 cents to $17.07 on 4 million shares Tuesday. The supplier of solar microinverters announced ...
Investors need to pay close attention to Pieris Pharmaceuticals (PIRS) stock based on the movements in the options market lately.
Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
By buying an index fund, investors can approximate the average market return. But if you choose individual stocks with prowess, you can make superior returns. For example, the Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) s...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! If you're interested in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), then youRead More...
The big shareholder groups in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have Read More...
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]
Steve Yoder has been the CEO of Pieris Pharmaceuticals Inc (NASDAQ:PIRS) since 2014. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
P.A.W. Capital Partners is a Greenwich-based hedge fund launched at the end of 1990 by its current Chief Investment Officer, General Partner and Senior Portfolio Manager, Peter A. Wright. After leading his fund for 28 years, and considering his previous work history, Peter Wright has more than 30 years of experience in the securities industry. […]
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 26.67% and 35.54%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Boston-based company said it had a loss of 11 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a ...
Pieris Pharmaceuticals Inc (NASDAQ:PIRS), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is PIRS Read More...